- Home
- MYN vs TERN Comparison
MYN vs TERN Comparison
Compare MYN & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- TERN
- Stock Information
- Founded
- MYN 1992
- TERN 2017
- Country
- MYN United States
- TERN United States
- Employees
- MYN N/A
- TERN N/A
- Industry
- MYN Finance Companies
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- TERN Health Care
- Exchange
- MYN Nasdaq
- TERN Nasdaq
- Market Cap
- MYN 411.5M
- TERN 382.2M
- IPO Year
- MYN N/A
- TERN 2021
- Fundamental
- Price
- MYN $10.24
- TERN $4.45
- Analyst Decision
- MYN
- TERN Buy
- Analyst Count
- MYN 0
- TERN 5
- Target Price
- MYN N/A
- TERN $18.30
- AVG Volume (30 Days)
- MYN 86.0K
- TERN 1.8M
- Earning Date
- MYN 01-01-0001
- TERN 03-13-2025
- Dividend Yield
- MYN 4.12%
- TERN N/A
- EPS Growth
- MYN N/A
- TERN N/A
- EPS
- MYN N/A
- TERN N/A
- Revenue
- MYN N/A
- TERN N/A
- Revenue This Year
- MYN N/A
- TERN N/A
- Revenue Next Year
- MYN N/A
- TERN N/A
- P/E Ratio
- MYN N/A
- TERN N/A
- Revenue Growth
- MYN N/A
- TERN N/A
- 52 Week Low
- MYN $8.47
- TERN $4.32
- 52 Week High
- MYN $10.62
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- MYN 52.37
- TERN 27.09
- Support Level
- MYN $10.00
- TERN $4.38
- Resistance Level
- MYN $10.25
- TERN $5.95
- Average True Range (ATR)
- MYN 0.09
- TERN 0.29
- MACD
- MYN 0.03
- TERN -0.09
- Stochastic Oscillator
- MYN 72.73
- TERN 4.46
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests primarily in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.